LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SRRK
Scholar Rock Holding Corporation
There isn't enough reported data to score SRRK yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SRRK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Weak | |
| Unavailable |
SRRK's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SRRK PE Valuation
SRRK has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SRRK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SRRK's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SRRK on earnings quality, reporting a profit while its opponent remains loss making.
SRRK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.22 | -$0.05 |
| Q2 2026 | -$3.31 | -$0.38 |
| Q1 2026 | -$3.45 | -$0.90 |
| Q4 2025 | -$3.29 | -$0.82 |
| Q3 2025 | -$3.17 | -$0.82 |
| Q2 2025 | -$2.93 | -$0.71 |
| Q1 2025 | -$2.55 | -$0.46 |
| Q4 2024 | -$2.47 | -$0.48 |
SRRK lost $3.22 per share over the past year, about the same as its loss the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SRRK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SRRK on profitability, with a higher operating margin.
SRRK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $33.2M | +605% |
| Q4 2021 | $4M | +18% |
| Q3 2021 | $5.5M | +80% |
| Q2 2021 | $4.6M | +18% |
| Q1 2021 | $4.7M | -6.4% |
| Q4 2020 | $3.4M | -55% |
SRRK's revenue is growing: $570,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18607% | N/A |
| Q1 2022 | -21% | +557 points |
| Q4 2021 | -873% | -114 points |
| Q3 2021 | -679% | +99 points |
| Q2 2021 | -659% | -160 points |
| Q1 2021 | -578% | -226 points |
| Q4 2020 | -760% | -597 points |
| Q3 2020 | -778% | N/A |
SRRK's operating margin was −18607% last quarter, down 17948 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SRRK on cash generation, producing positive trailing cash flow while its opponent burns cash.
SRRK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$81.9M | -$12.9M |
| Q2 2026 | -$70.3M | +$6.8M |
| Q1 2026 | -$82.2M | -$3.2M |
| Q4 2025 | -$75.5M | -$26M |
| Q3 2025 | -$69M | -$16.5M |
| Q2 2025 | -$77.2M | -$27.9M |
| Q1 2025 | -$78.9M | -$29.1M |
| Q4 2024 | -$49.5M | -$12.2M |
SRRK has burned cash in almost every quarter: −$310M over the past year, against −$275M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SRRK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SRRK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +1.8M shares |
| 1 year | +16% | +18.6M shares |
| 3 years | +64% | +51.8M shares |
| 5 years | +262% | +95.8M shares |
| Available history | +381% | +105M shares |
SRRK has 132M diluted shares, up 16% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SRRK Net Leverage
SRRK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SRRK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 25.9 | Neutral |
SRRK's weekly RSI is 44 (neutral) and its Stochastic is 26 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SRRK PE vs Healthcare Sector
SRRK has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SRRK on trend strength, trading above more of its moving averages.
SRRK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.1 | 2.2% below |
| 20 week MA | $49.5 | 13% below |
| 50 week MA | $47.5 | 9.2% below |
| 100 week MA | $41.5 | 4.1% above |
| 200 week MA | $27.1 | 59% above |
SRRK has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 59% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SRRK on returns for 2026, with the stronger performance.
SRRK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.0 | $51.5 | +296% |
| 2021 | $51.5 | $25.4 | -51% |
| 2022 | $25.4 | $7.97 | -69% |
| 2023 | $7.97 | $18.8 | +136% |
| 2024 | $18.8 | $44.5 | +136% |
| 2025 | $44.5 | $45.7 | +2.7% |
| 2026 YTD | $45.7 | $43.2 | -5.5% |
SRRK's yearly returns have swung widely, from +296% in 2020 to −69% in 2022. It's down 5.5% so far in 2026.